NEW YORK (GenomeWeb) – Cantor Fitzgerald on Tuesday initiated coverage of urine-based liquid biopsy firm Trovagene with a Buy rating and a $10 target price on the firm's stock. 

Analyst Bryan Brokmeier said in a research report that the company's differentiated approach to cancer detection and monitoring positions it to be "a leading player in the cancer diagnostics market." 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

In Science this week: International Wheat Genome Sequencing Consortium publishes the bread wheat cultivar Chinese Spring reference genome, and more.

At his FDA Law Blog, Jeffrey Gibbs discusses FDA's technical assistance for the draft Diagnostic Accuracy and Innovation Act.

The New York Times reports that genetic testing has uncovered unfaithful penguins at a Utah aquarium.

Cancer researcher loses funding under new Wellcome Trust anti-bullying policies, the Guardian reports.

Sponsored by
Canon BioMedical

This webinar will provide an overview of recent advances in single-cell RNA sequencing from the perspectives of three research organizations.